tbuckley/cabot-search huggingface dataset:
Association of plasma CXCL12 level and bone metastasis in advance stage non-small cell lung cancer patients in King Chulalongkorn Memorial Hospital.
Authors: Sunee Neesanun, Virote Sriuranpong
Journal: Journal of Clinical Oncology (2015)

e19099 Background: Bone is a common metastasis site in advance stage NSCLC and a half of them occurred skeleton related event. Although the sensitivity of bone scan is quite high, its specificity is not satisfactory due to false positive or false negative in osteolytic lesion. CXCL12/CXCR4 axis is the one role of various cancer metastasis included NSCLC and bone metastasis in prostate cancer. In the past, there were studies showed that higher plasma CXCL12 in NSCLC patients versus normal population, higher CXCL12 in malignant pleural effusion versus non-malignant pleural effusion. Methods: In this study, cross-sectional analytic study, we enrolled patients with advance stage NSCLC in KCMH during May 2013–January 2014. We collection of blood was taken place before systemic treatment to compare plasma CXCL12 level in patients who had bone metastasis versus no bone metastasis for primary endpoint. Secondary endpoint was evaluating correlation plasma CXCL12 with other organ metastasis. Results: Total eligible patients were 89, 41 patients were NSCLC with bone metastasis, 48 patients were NSCLC without bone metastasis. Mean plasma CXCL12 in bone metastasis patients was 2284.49±475.40 pg/ml, no bone metastasis was 2062.93±717.93 pg/ml and local bone invasion was 2995.75±358.85 pg/ml (P = 0.048). Plasma CXCL 12 in group of bone metastasis only was 2401.95±475.619 pg/ml, combinded metastasis 2292.49 ± 501.76 pg/ml, non bone metastasis 1893.91±75688.79 pg/ml respectively (P = 0.012). Plasma CXCL12 was highest in organ metastasis ≥ 3 organ 2349.34 ± 529.35 , and lowest in 0-1 organ metastasis 2125.57 ± 699.19 pg/ml (P = 0.485) Conclusions: The result showed high plasma CXCL12 in NSCLC patient who had bone metastasis and multiple organ metastases. Subgroup analysis who had merely bone metastasis was highest CXCL12 level and combinded metastasis higher CXCL12 than who had non bone metastasis. In conclusion, Our results demonstrate a correlation between plasma CXCL12 and bone metastasis in NSCLC patients. Plasma CXCL12 is may be an important cytokine for cancer metastasis.
THU-304-Modeling NAFLD-related disease progression among the PITER SVR12 cohort
Authors: Chris Estes, Loreta Kondili, Maria Giovanna Quaranta, Antonio Craxi, Salvatore Petta, Mario Masarone, Francesco Paolo Russo, Massimo Siciliano, Barbara Coco, Roberto Filomia, Homie Razavi
Journal: Journal of Hepatology (2019)
Abstract 142: Relationship Between End Tidal CO2 and Hemodynamic Flow in a Swine Model of Prolonged Cardiac Arrest
Authors: Joshua W Lampe, Tai Yin, Josiah D Garcia, George Bratinov, Theodore Weiland, Christopher L Kaufman, Lance B Becker
Journal: Circulation (2013)

Introduction: There is growing consensus that end-tidal CO2 (ETCO2) is a surrogate for blood flow and quality of chest compressions in cardiac arrest. From a hemodynamic perspective, cardiac arrest...
Retrograde single-balloon enteroscopy for a symptomatic, unusual, ileal polypoid lesion
Authors: Nicola Olivari, Sebastian Manuel Milluzzo, Denise Bianchi, Cristiano Spada
Journal: Endoscopy (2019)

Meckel’s diverticulum is a remnant of the omphalomesenteric duct, which is normally obliterated between the 5th and 8th week of gestation. It occurs in 2 % of the population [1] and it is often an incidental finding. Anatomically, Meckel’s diverticulum comprises all layers of the intestinal wall and, in approximately 50 % of cases, contains ectopic tissues which can cause complications. Meckel’s diverticulum can cause abdominal pain, bleeding, and intestinal obstruction but is rarely symptomatic (4 %) [2]. Adult intussusception due to an inverted Meckel’s diverticulum has also been reported [3].
Response to Comment on Mulukutla et al. Autoantibodies to the IA-2 Extracellular Domain Refine the Definition of “A+” Subtypes of Ketosis-Prone Diabetes. Diabetes Care 2018;41:2637–2640
Authors: Surya N. Mulukutla, Maria Acevedo-Calado, Christiane S. Hampe, Massimo Pietropaolo, Ashok Balasubramanyam
Journal: Diabetes Care (2019)

We thank Dr. Heneberg (1) for the comments regarding our article (2) describing autoantibody responses to the IA-2 extracellular domain in ketosis-prone diabetes (KPD).

We agree that the intracellular domain of the neuroendocrine autoantigen IA-2 (amino acid residues 605–979) represents the immunodominant region of the molecule. In fact, both autoantibody and autoreactive T-cell responses from patients with type 1 diabetes recognize peptides localized within the intracellular domain of IA-2 (IA-2IC) (3). Nonetheless, we identified autoantibody and T-cell responses specifically directed to the IA-2 extracellular domain (IA-2EC) in individuals with or without antibodies against IA-2IC (4). Our recent studies demonstrate that IA-2EC is a target of humoral immune responses in a subgroup of patients with KPD (2). To demonstrate specificity of …
SAT-333-Non-alcoholic steatohepatitis significantly decreases microsomal liver function in the absence of fibrosis, which allows the use of the 13C-aminopyrine breath test for its non-invasive detection
Authors: Wim Verlinden, Eugénie Van Mieghem, Laura Depauw, Thomas Vanwolleghem, Peter Michielsen, Luisa Vonghia, An Verrijken, Eveline Dirinck, Luc Van Gaal, Sven Francque
Journal: Journal of Hepatology (2019)
Leveraging deep learning to understand health beliefs about the Human Papillomavirus Vaccine from social media
Authors: Jingcheng Du, Rachel M. Cunningham, Yang Xiang, Fang Li, Yuxi Jia, Julie A. Boom, Sahiti Myneni, Jiang Bian, Chongliang Luo, Yong Chen, Cui Tao
Journal: npj Digital Medicine (2019)

Abstract Our aim was to characterize health beliefs about the human papillomavirus (HPV) vaccine in a large set of Twitter posts (tweets). We collected a Twitter data set related to the HPV vaccine from 1 January 2014, to 31 December 2017. We proposed a deep-learning-based framework to mine health beliefs on the HPV vaccine from Twitter. Deep learning achieved high performance in terms of sensitivity, specificity, and accuracy. A retrospective analysis of health beliefs found that HPV vaccine beliefs may be evolving on Twitter.
PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection
Authors: Ohad Etzion, Saeed Sadiq Hamid, Yoav Lurie, Edward Gane, Nimrah Bader, David Yardeni, a Nevo-Shor, sm channa, Minaz Mawani, Om Parkash, Kyunghee Yang, Diane Longo, Robert G. Gish, Jeffrey Glenn, David Apelian
Journal: Journal of Hepatology (2019)
Early and late brain metastases in EGFR wild type and EGFR mutation positive non small cell lung cancer: Implications for survival.
Authors: Cheryl Ho, Andrew Yamada, Britta Weber, Ren Yuan
Journal: Journal of Clinical Oncology (2015)

e19065 Background: EGFR mutation positivity (EGFR+) is a known favorable prognostic factor in NSCLC. We sought to understand its significance in the setting of brain metastases (BM) when compared to EGFR wild type (WT) patients. We evaluated the difference between early versus late BM ( < = 6 vs > 6 months from diagnosis) in EGFR+ and WT patients with respect to radiographic patterns and the impact on overall survival (OS). Methods: A retrospective study was conducted in patients with stage IV non-squamous NSCLC and known EGFR mutation status who underwent whole brain radiotherapy or surgical resection of BM from Mar 2010 - Dec 2012 at British Columbia Cancer Agency. The data was divided into WT and EGFR+ patients, early and late BM groups to characterize the radiographic patterns and OS from initial NSCLC diagnosis (dx) and BM dx. Results: A cohort of 430 patients was composed of 327 WT (206 early vs 121 late) and 103 EGFR+ (65 early vs 38 late). Pattern of BM in WT showed more frequent leptomeningeal disease in late compared to early BM (8% vs. 2%, p = 0.01) and no difference in size of largest BM, number of metastases or cerebral edema. Pattern of BM in EGFR+ showed a trend towards a miliary pattern in late BM (p = 0.058) and no difference in size of largest BM, cerebral edema or leptomeningeal spread. Median OS from initial dx in EGFR WT was early: 7.1 m vs. late: 24.9 m (p < 0.001) and OS from BM dx was 6.3 m vs. 4.9 m respectively (p = 0.67). Median OS from initial dx in EGFR+ was early: 19.9 m vs. late: 25.6 m (p = 0.39) and OS from BM dx early: 19.2 m vs. late: 3.9 m (p < 0.001). The Cox proportional hazards model including sex, age, PS, systemic treatment and BM timing showed that early BM were associated with poor survival outcomes in the EGFR WT patients, while it did not impact survival in EGFR+ patients. Conclusions: OS in EGFR+ patients is comparable between early and late BM, suggesting EGFR positivity and associated EGFR tyrosine kinase inhibitor treatment are stronger prognostic and predictive factors for survival than BM. In contrast, early BM is a significant negative prognostic indicator for survival in EGFR WT patients. The radiographic pattern of BM is different between WT and EGFR+ patients.
SAT-162-Serum HBV RNA as a predictor of incomplete HBV DNA suppression following initiation of nucleoside therapy in HBV/HIV co-infected individuals
Authors: Ruth Byrne, Mary Horner, Matthew Bruce, Jeffrey Gersch, Mary Kuhns, Gavin Cloherty, Kosh Agarwal, Ivana Carey
Journal: Journal of Hepatology (2019)
TCTAP C-166 Aortic Aneurysm Treated by Aortic Stent-graft Combined with Occlusion Device: Tips and Pitfalls to Rescue the Covered Left Carotid Artery
Authors: Quang Ngoc Nguyen, Than Xuan Le, Hung Manh Pham
Journal: Journal of the American College of Cardiology (2019)
Current Landscape of Immunotherapy in Breast Cancer
Authors: Sylvia Adams, Margaret E. Gatti-Mays, Kevin Kalinsky, Larissa A. Korde, Elad Sharon, Laleh Amiri-Kordestani, Harry Bear, Heather L. McArthur, Elizabeth Frank, Jane Perlmutter, David B. Page, Benjamin Vincent, Jennifer F. Hayes, James L. Gulley, Jennifer K. Litton, Gabriel N. Hortobagyi, Stephen Chia, Ian Krop, Julia White, Joseph Sparano, Mary L. Disis, Elizabeth A. Mittendorf
Journal: JAMA Oncology (2019)

There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at the time of this narrative review. The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease.After searching ClinicalTrials.gov on April 24, 2018, and PubMed up to June 30, 2018, to identify breast cancer immunotherapy trials, we found that immune checkpoint blockade (ICB) is the most investigated form of immunotherapy in breast cancer. Use of ICB as monotherapy has achieved objective responses in patients with breast cancer, with higher rates seen when administered in earlier lines of therapy. For responding patients, those responses are durable. More recent data suggest clinical efficacy when ICB is given in combination with chemotherapy. Ongoing studies are evaluating combination strategies pairing ICB with additional chemotherapeutic agents, targeted therapy, vaccines, and local ablative therapies to enhance response. To date, robust predictive biomarkers for response to ICB have not been established.It is anticipated that combination therapy strategies will be the way forward for immunotherapy in breast cancer, with an improved understanding of tumor, microenvironment, and host factors informing treatment combination decisions. Thoughtful study design incorporating appropriate end points and correlative studies will be critical in identifying optimal strategies for enhancing the immune response against breast tumors.
A Study of the Human Heart as a Multiple Dipole Electrical Source
Authors: JOHN H. HOLT, ANTHONY C.L. BARNARD, M. STUART LYNN, JOHN O. KRAMER
Journal: Circulation (1969)

The multiple dipole electrocardiographic (MDECG) method proposed earlier was evaluated further by testing its ability to diagnose and quantitate right ventricular hypertrophy (RVH). Two series of subjects were used. The first series consisted of patients with conditions giving a pressure overload of the right ventricle (RV), the RV systolic pressure (RVSP) being used to indicate the severity of RVH. The second series consisted of patients for whom a surgeon's visual estimate of RV size was available. A series of normal subjects was also used. For the first series a sensitivity of 85% for RVH diagnosis by MDECG was obtained, the specificity based on the normal series being 94%. The second, more inhomogeneous, series yielded a sensitivty of 75% and a specificity of 75%. This diagnostic performance was better than that obtained with conventional electrocardiographic or vectorcardiographic methods applied to the same patients. To assess the quantitative ability of the MDECG, the results obtained for the first series were correlated with RVSP. A coefficient of determination for r 2 of 86% (standard error of RVSP estimate being 11 mm Hg) was obtained.
PS-153-The pre-s2 deletion HBVmutants are responsible for the intracellular accumulation of the HBS protein, ER stress and mitochondria dysfunction
Authors: Jenny Yuh-Jin Liang, Rui-Dung Teng, Cheng-Pu Sun, Chien-Wei Su, Ming-Hua Tao, Jaw-Ching Wu
Journal: Journal of Hepatology (2019)
Abstract 17671: TCF21 Regulates Coronary Artery Disease Causing Aryl-hydrocarbon Receptor Gene Expression and its Downstream Pathway Activation by Environmental Ligands
Authors: Juyong B Kim, Milos Pjanic, Olga Sazanova, Tina Wang, Clint Miller, Thomas Quertermous
Journal: Circulation (2015)

Background: Recently, the TCF21 gene was linked to the highly replicated coronary artery disease (CAD) associated polymorphism in the 6q23 locus. TCF21 is especially compelling as a causal gene since it is a transcription factor that is known to play a critical role in the development of coronary arteries. One downstream target gene identified through preliminary studies was AHR. AHR is a ligand-activated transcription factor that mediates the cellular response to environmental contaminants, including dioxin and polycyclic aromatic hydrocarbons (eg. cigarette smoke), and has recently been associated with CAD in mice and humans. We set out to identify the TCF21 downstream pathways that are related to CAD. Methods: We performed chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA-sequencing using primary human coronary artery smooth muscle cells (HCASMC) to survey the targets of TCF21 binding and the regulated downstream pathways. The peaks from ChIP-Seq were identified using MACSv2 according to ENCODE parameters. RNA-Seq was analyzed using edgeR to identify the differentially expressed genes. The effect of TCF21 on Aryl-hydrocarbon receptor (AHR) pathway activation was tested using knockdown and overexpression lentivirus transduction of HCASMC followed by 2,3,7,8-Tetrachlorodibenxo- p -dioxin (TCDD) treatment and qPCR. Results: RNA-Seq studies identified AHR as a significantly regulated mRNA downstream of TCF21 (p=1.4x10 -5 ). Also, the ChIP-Seq identified multiple TCF21 binding peaks in the AHR gene. We found a significant overlap of the AHR and TCF21 binding peaks (p&lt;1x10 -15 ) and genes differentially regulated by TCF21 and AHR (p=1x10 -5 ), among publicly available datasets. Furthermore, we found that the TCF21 level modulated the magnitude of the ligand-dependent activation of AHR pathway genes by TCDD. Conclusion: We identified a novel interaction between TCF21 and AHR, a gene involved in environmental xenobiotic response that was recently associated with CAD. The functional link between TCF21 and AHR provides an opportunity to explore gene by environment interactions in the pathogenesis of CAD.
Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP
Authors: Siyuan Jiang, Xuetong Wang, Dalong Song, XiaoJun Liu, Yinmin Gu, Zhiyuan Xu, Xiaodong Wang, Xiaolu Zhang, Qinong Ye, Zhou Tong, BingXue Yan, Jie Yu, Yunzhao Chen, Minxuan Sun, Yang Wang, Shan Gao
Journal: Cancer Research (2019)

Cholesterol increases the risk of aggressive prostate cancer and has emerged as a potential therapeutic target for prostate cancer. The functional roles of cholesterol in prostate cancer metastasis are not fully understood. Here, we found that cholesterol induces the epithelial-to-mesenchymal transition (EMT) through extracellular-regulated protein kinases 1/2 pathway activation, which is mediated by EGFR and adipocyte plasma membrane-associated protein (APMAP) accumulation in cholesterol-induced lipid rafts. Mechanistically, APMAP increases the interaction with EGFR substrate 15-related protein (EPS15R) to inhibit the endocytosis of EGFR by cholesterol, thus promoting cholesterol-induced EMT. Both the mRNA and protein levels of APMAP are upregulated in clinical prostate cancer samples. Together, these findings shed light onto an APMAP/EPS15R/EGFR axis that mediates cholesterol-induced EMT of prostate cancer cells. SIGNIFICANCE: This study delineates the molecular mechanisms by which cholesterol increases prostate cancer progression and demonstrates that the binding of cholesterol-induced APMAP with EPS15R inhibits EGFR internalization and activates ERK1/2 to promote EMT. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/12/3063/F1.large.jpg.
SAT-419-Endotrophin, a fragment of collagen type VI formation (PRO-C6) is associated with progression free survival and mortality in patients with hepatocellular carcinoma
Authors: Signe Holm Nielsen, Raj Uchila, Mohammed Eslam, Mette Juul Nielsen, Diana Leeming, Roslyn Vongsuvanh, David Van Der Poorten, Morten Karsdal, Jacob George
Journal: Journal of Hepatology (2019)
SAT-411-Clinical comparison and conversion of international normalized ratio and prothrombin index
Authors: Paul Cales, Marie Tuffigo, Frédéric Oberti, Virginie Planche, Jerome Boursier, Isabelle Fouchard Hubert, Lannes Adrien, Alban Godon, Christophe Corpechot, Valérie Ugo
Journal: Journal of Hepatology (2019)
THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection
Authors: Marianne Martinello, Chloe Orkin, Graham Cooke, Sanjay Bhagani, Edward Gane, Ranjababu Kulasegaram, David Shaw, Elise Tu, Ecaterina Filep, Kathy Petoumenos, Pip Marks, Tanya Applegate, Jason Grebely, Gregory Dore, Mark Nelson, Gail Matthews
Journal: Journal of Hepatology (2019)
The Diabetes Story: A Call to Action
Authors: Jane E.B. Reusch
Journal: Diabetes Care (2019)

A presidential address of the American Diabetes Association (ADA) provides an opportunity to have a voice, the stage, and the pulpit, so to speak. For what purpose? To increase awareness and urgency around the crisis that diabetes poses to the individual and to the world. Each official outreach to the diabetes community as President of Medicine & Science presents an opportunity to tell an important story: the story of the magnitude of the diabetes crisis. In this address, I will provide the reader with important facts about the diabetes epidemic in hopes that you, each of you, will tell the story of diabetes early and often. I believe that tangible awareness of this crisis can change this story for the lives of people with diabetes and impact the global health and financial burden of diabetes.

Storytelling is a potent strategy for conveying both information and inspiration about a topic. By weaving together the individual reality and the global health burden of the inadequately addressed diabetes epidemic, we can frame the urgent and misunderstood diabetes epidemic as a story: a story that will create the impetus for action. In the next few sections, I will highlight the key elements of the 24/7/365 burden of diabetes on an individual and the unaddressed issues for people living with diabetes. Next, I will present the facts regarding the U.S. and global epidemic including the life span– and health span–shortening complications of diabetes. I will emphasize the unsustainable economic implications of 30 million in the U.S. and 425 million globally living with diabetes (1,2). Next, I will discuss the urgent need of a health care delivery system to address the life-threatening reality of lack of accessible health care and medications and the unaddressed reality of the psychosocial impact and stigma and consequences of …
Improving fitness after childhood cancer: A novel exercise clinic for pediatric oncology patients.
Authors: Vicky Rowena Breakey, Dena Zeraatkar, Burke Baird, Brian Timmons
Journal: Journal of Clinical Oncology (2015)

e21030 Background: Despite emerging evidence for exercise interventions to improve the fitness of survivors of childhood cancer, there remain few examples in the clinical setting. In January 2013, referral to the EX MED clinic became standard for all patients that complete cancer therapy in our program. This is a retrospective review of the initial cohort of patients who have been referred to the clinic in the first two years. Methods: The EX MED team consists of a pediatrician, an exercise physiologist, and a kinesiologist. At the initial visit, every able patient performed a cycle ergometer test of aerobic fitness, measured as peak mechanical power output (Watts/kg body mass). Each patient was given an individualized exercise prescription to address fitness goals. Patients were invited to follow-up every 3-6 months for reassessment of aerobic fitness. A 10% increase in peak mechanical power output was defined as a clinically significant improvement. Results: Over the course of 25 months, 23 patients qualified for referral. Of those, 16 attended and 7 declined. Of the 16 patients, 5 attended only the initial consultation and 11 attended subsequent assessments (range 2 to 6 appointments). Of the 10 patients who attended > 1 appointment and completed the cycle ergometer test, 9 (90%; 95% CI: 71% — 100%) showed a clinically significant improvement in aerobic fitness. Clinic attendance did not have a significant impact on BMI, with 5 (45%; 95% CI 16% — 74%) being classified as overweight ( > +1 SD) and 5 (45%; 95% CI 16% — 74%) as obese ( > +2 SD) both before and after. No significant correlations were found between patients' clinical history (diagnosis and treatment course) and their performance at the EX MED clinic. Conclusions: The EX MED clinic is providing a novel opportunity for pediatric cancer survivors to obtain fitness testing and receive exercise counseling. High rates of return for subsequent assessments, suggests patient satisfaction with the program. Early results show improvement in fitness. This work lays the foundation for a more in-depth, prospective, longitudinal look at the impact of the EX MED clinic on survivors of childhood cancer.
Author Correction: An atlas of genetic influences on osteoporosis in humans and mice
Authors: John A. Morris, John P. Kemp, Scott E. Youlten, Laetitia Laurent, John G. Logan, Ryan C. Chai, Nicholas A. Vulpescu, Vincenzo Forgetta, Aaron Kleinman, Sindhu T. Mohanty, C. Marcelo Sergio, Julian Quinn, Loan Nguyen-Yamamoto, Aimee-Lee Luco, Jinchu Vijay, Marie-Michelle Simon, Albena Pramatarova, Carolina Medina-Gomez, Katerina Trajanoska, Elena J. Ghirardello, Natalie C. Butterfield, Katharine F. Curry, Victoria D. Leitch, Penny C. Sparkes, Anne-Tounsia Adoum, Naila S. Mannan, Davide S. K. Komla-Ebri, Andrea S. Pollard, Hannah F. Dewhurst, Thomas A. D. Hassall, Michael-John G. Beltejar, Douglas J. Adams, Suzanne M. Vaillancourt, Stephen Kaptoge, Paul Baldock, Cyrus Cooper, Jonathan Reeve, Evangelia E. Ntzani, Evangelos Evangelou, Claes Ohlsson, David Karasik, Fernando Rivadeneira, Douglas P. Kiel, Jonathan H. Tobias, Celia L. Gregson, Nicholas C. Harvey, Elin Grundberg, David Goltzman, David J. Adams, Christopher J. Lelliott, David A. Hinds, Cheryl L. Ackert-Bicknell, Yi-Hsiang Hsu, Matthew T. Maurano, Peter I. Croucher, Graham R. Williams, J. H. Duncan Bassett, David M. Evans, J. Brent Richards
Journal: Nature Genetics (2019)